Cargando…

Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis

The amyloid deposits that cause disease in systemic amyloidosis always contain the normal plasma protein, serum amyloid P (SAP) component. SAP is the target of a novel immunotherapy approach now being developed to eliminate amyloid deposits. The treatment is enabled by, and critically depends on, th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahota, T, Berges, A, Barton, S, Cookson, L, Zamuner, S, Richards, D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360666/ https://www.ncbi.nlm.nih.gov/pubmed/26225229 http://dx.doi.org/10.1002/psp4.15

Ejemplares similares

Interaction of serum amyloid P component with hexanoyl bis(d-proline) (CPHPC)
por: Kolstoe, Simon E., et al.
Publicado: (2014)

A Tutorial on Target-Mediated Drug Disposition (TMDD) Models
por: Dua, P, et al.
Publicado: (2015)

Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
por: Brekkan, A., et al.
Publicado: (2018)

Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification
por: Peletier, Lambertus A., et al.
Publicado: (2012)

Target‐Mediated Drug Disposition Model for Bispecific Antibodies: Properties, Approximation, and Optimal Dosing Strategy
por: Schropp, Johannes, et al.
Publicado: (2019)

A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback
por: Aston, Philip J., et al.
Publicado: (2016)

Model-Based Assessment of Dosing Strategies in Children for Monoclonal Antibodies Exhibiting Target-Mediated Drug Disposition
por: Zheng, S, et al.
Publicado: (2014)

Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring
por: Lemmens, Glenn, et al.
Publicado: (2021)

Sex Differences in Drug Disposition
por: Soldin, Offie P., et al.
Publicado: (2011)

Liver‐directed drugs for transthyretin‐mediated amyloidosis
por: Brannagan, Thomas H., et al.
Publicado: (2022)

Target‐Mediated Drug Disposition Pharmacokinetic/Pharmacodynamic Model‐Informed Dose Selection for the First‐in‐Human Study of AVB‐S6‐500
por: Bonifacio, Laura, et al.
Publicado: (2019)

Intracellular drug bioavailability: a new predictor of system dependent drug disposition
por: Mateus, André, et al.
Publicado: (2017)

Pharmacokinetic Models for FcRn-Mediated IgG Disposition
por: Xiao, Jim J.
Publicado: (2012)

Phenobarbital for Alcohol Withdrawal: Rapid Patient Disposition
por: Richards, John R.
Publicado: (2000)

Association of Blood Alcohol and Alcohol Use Disorders with Emergency Department Disposition of Trauma Patients
por: Hoonpongsimanont, Wirachin, et al.
Publicado: (2022)

FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
por: Brenner, Mitchell C., et al.
Publicado: (2016)

Dispositions : a debate /
por: Armstrong, D. M. (David Malet), 1926-
Publicado: (1996)

Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model
por: Snelder, Nelleke, et al.
Publicado: (2020)

A target‐mediated drug disposition population pharmacokinetic model of GC1118, a novel anti‐EGFR antibody, in patients with solid tumors
por: Chung, Tae Kyu, et al.
Publicado: (2021)

An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study
por: Richards, Duncan, et al.
Publicado: (2022)

Treatment With Antipsychotics in Pregnancy: Changes in Drug Disposition
por: Westin, Andreas A., et al.
Publicado: (2017)

Racial Disparity in Drug Disposition in the Digestive Tract
por: Gao, Song, et al.
Publicado: (2021)

Dispositional Awe and Online Altruism: Testing a Moderated Mediating Model
por: Lin, RongMao, et al.
Publicado: (2021)

Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography
por: Hernández Lozano, Irene, et al.
Publicado: (2019)

Psychopathy and chronotype disposition: the mediating role of depression
por: Akram, Umair, et al.
Publicado: (2019)

Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies
por: Djebli, Nassim, et al.
Publicado: (2017)

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials
por: Henderson, C.J., et al.
Publicado: (2019)

Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability
por: Tsunoda, Shirley M., et al.
Publicado: (2021)

Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
por: Lucas, Andrew T., et al.
Publicado: (2019)

Mechanistic Models as Framework for Understanding Biomarker Disposition: Prediction of Creatinine‐Drug Interactions
por: Scotcher, Daniel, et al.
Publicado: (2020)

A physiologically‐based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites
por: Ramachandran, Aparna, et al.
Publicado: (2023)

Modeling Kinetics of Subcellular Disposition of Chemicals
por: Balaz, Stefan
Publicado: (2009)

Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics
por: Mooij, Miriam G., et al.
Publicado: (2015)

Challenges and advances in the assessment of the disposition of antibody‐drug conjugates
por: Kamath, Amrita V., et al.
Publicado: (2015)

In vitro and in vivo drug disposition of cilengitide in animals and human
por: Dolgos, Hugues, et al.
Publicado: (2016)

Editorial of Special Issue on Drug Metabolism and Disposition in Diseases
por: Xie, Wen
Publicado: (2020)

Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis
por: Morgan, Gareth J.
Publicado: (2021)

Disposition générale
Publicado: (1966)

Representing dispositions
por: Röhl, Johannes, et al.
Publicado: (2011)

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: Ternant, David, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_56839pslvmvl90lbmpfagrr3ij